Extended Data Table 2 Treatment-emergent adverse events

From: Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

  1. Treatment-emergent adverse events (TEAEs) were defined as adverse events that are definitely, highly likely, or possibly related to the investigational agents occurring at any time whilst a patient was on study.
  2. Data are n (%). Treatment-related adverse events of 23 patients were included the safety analysis.
  3. G = grade according to NCI CTCAE v4.0.
  4. *Two of 23 patients were not evaluable for DLT due to early cessation of the study drugs due to progressive disease before completing the DLT period; one patient died on study likely due to progressive disease after 6 days on study.
Back to article page